» Articles » PMID: 1369522

Results of Partial Mandibulectomy for the Treatment of Oral Tumors in 142 Dogs

Overview
Journal Vet Surg
Date 1991 Nov 1
PMID 1369522
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Partial mandibulectomy was performed for the treatment of benign or malignant oral tumors in 142 dogs. Forty-two dogs with a benign tumor (ameloblastoma) had a 22.5 month (range, 6 to 74 months) median disease-free interval, with a 97% 1-year survival rate; there was local recurrence in one dog. Twenty-four dogs with squamous cell carcinoma had a disease-free interval of 26 months (range, 6 to 84 months), with a 91% 1-year survival rate; recurrence and metastasis developed in two dogs and metastatic disease in one dog. Based on survival curves, 37 dogs with a melanoma had a median survival time of 9.9 months (range, 1 to 36 months), with a 21% 1-year survival rate; 20 dogs died or were euthanatized for recurrent or metastatic disease. Twenty dogs with osteosarcoma had a median survival time of 13.6 months (range, 3 to 28 months), with a 35% 1-year survival rate; nine dogs died or were euthanatized for recurrent or metastatic disease. Nineteen dogs with fibrosarcoma had median survival time of 10.6 months (range, 3 to 32 months), with a 50% 1-year survival rate; 12 dogs died or were euthanatized for recurrent or metastatic disease. Results of this and previous studies demonstrated that partial mandibulectomy was effective in prolonging survival and decreasing recurrence for squamous cell carcinoma and ameloblastoma. Progressive disease and corresponding low survival times were common in dogs with melanoma, osteosarcoma, and fibrosarcoma. There were no differences in survival times or the progression of disease among five partial hemimandibulectomy procedures. The high rates of recurrence and metastasis in dogs with these tumors suggest a need for evaluation of ancillary chemotherapy and local radiation therapy to decrease the prevalence of progressive disease.

Citing Articles

Establishment of Canine Oral Mucosal Melanoma Cell Lines and Their Xenogeneic Animal Models.

Li S, Liu Z, Lv J, Lv D, Xu H, Shi H Cells. 2024; 13(11.

PMID: 38891124 PMC: 11171988. DOI: 10.3390/cells13110992.


Canine Oral Melanoma: Questioning the Existing Information through a Series of Clinical Cases.

Perez-Santana C, Jimenez-Alonso A, Rodriguez-Esparragon F, Cazorla-Rivero S, Rodriguez Grau-Bassas E Vet Sci. 2024; 11(5).

PMID: 38787198 PMC: 11125799. DOI: 10.3390/vetsci11050226.


Treatment of Canine Oral Melanomas: A Critical Review of the Literature.

Pazzi P, Steenkamp G, Rixon A Vet Sci. 2022; 9(5).

PMID: 35622724 PMC: 9147014. DOI: 10.3390/vetsci9050196.


Surgical Margins for Ameloblastoma in Dogs: A Review With an Emphasis on the Future.

Goldschmidt S Front Vet Sci. 2022; 9:830258.

PMID: 35392113 PMC: 8980539. DOI: 10.3389/fvets.2022.830258.


A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy × 6 radiotherapy protocol.

Baja A, Kelsey K, Ruslander D, Gieger T, Nolan M Vet Comp Oncol. 2022; 20(3):623-631.

PMID: 35338766 PMC: 9539951. DOI: 10.1111/vco.12815.